BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8790398)

  • 21. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
    Kropshofer H; Vogt AB; Hämmerling GJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
    Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
    J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
    Neumann J; Eis-Hübinger AM; Koch N
    J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.
    Fling SP; Rak J; Muczynski KA; Arp B; Pious D
    J Exp Med; 1997 Nov; 186(9):1469-80. PubMed ID: 9348304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
    Ullrich HJ; Döring K; Grüneberg U; Jähnig F; Trowsdale J; van Ham SM
    Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13163-8. PubMed ID: 9371817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes.
    Zhou Z; Callaway KA; Weber DA; Jensen PE
    J Immunol; 2009 Oct; 183(7):4187-91. PubMed ID: 19767569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
    Chou CL; Sadegh-Nasseri S
    J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
    Denzin LK; Cresswell P
    Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
    Vogt AB; Kropshofer H; Hämmerling GJ
    Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The kinetic basis of peptide exchange catalysis by HLA-DM.
    Zarutskie JA; Busch R; Zavala-Ruiz Z; Rushe M; Mellins ED; Stern LJ
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12450-5. PubMed ID: 11606721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
    Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
    J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM.
    Lightstone L; Hargreaves R; Bobek G; Peterson M; Aichinger G; Lombardi G; Lechler R
    Proc Natl Acad Sci U S A; 1997 May; 94(11):5772-7. PubMed ID: 9159149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
    Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
    Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.
    Avva RR; Cresswell P
    Immunity; 1994 Dec; 1(9):763-74. PubMed ID: 7895165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules.
    Marin-Esteban V; Falk K; Rötzschke O
    J Biol Chem; 2004 Dec; 279(49):50684-90. PubMed ID: 15381703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.